Millennium Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.6M Sell
389,900
-160,800
-29% -$9.37M 0.01% 1421
2025
Q4
$29.7M Sell
550,700
-240,400
-30% -$11.6M 0.01% 1198
2025
Q3
$35.7M Buy
791,100
+301,800
+62% +$14.1M 0.02% 1114
2025
Q2
$22.6M Buy
489,300
+79,100
+19% +$3.88M 0.01% 1454
2025
Q1
$25M Sell
410,200
-70,600
-15% -$4.12M 0.01% 1313
2024
Q4
$27.2M Sell
480,800
-213,000
-31% -$11.9M 0.01% 1266
2024
Q3
$35.9M Buy
693,800
+83,100
+14% +$3.9M 0.02% 1060
2024
Q2
$25.4M Buy
610,700
+19,500
+3% +$873K 0.01% 1294
2024
Q1
$32.1M Sell
591,200
-165,700
-22% -$8.44M 0.01% 1149
2023
Q4
$38.8M Sell
756,900
-2,873,300
-79% -$151M 0.02% 976
2023
Q3
$211M Buy
3,630,200
+2,606,100
+254% +$160M 0.11% 134
2023
Q2
$65.5M Sell
1,024,100
-1,048,400
-51% -$70.3M 0.03% 570
2023
Q1
$144M Sell
2,072,500
-595,400
-22% -$42M 0.08% 198
2022
Q4
$192M Buy
2,667,900
+1,170,500
+78% +$88.3M 0.11% 147
2022
Q3
$106M Buy
1,497,400
+662,600
+79% +$48.1M 0.06% 295
2022
Q2
$64.3M Buy
834,800
+191,200
+30% +$14.6M 0.04% 503
2022
Q1
$47M Buy
643,600
+255,700
+66% +$17.2M 0.02% 733
2021
Q4
$24.2M Sell
387,900
-578,700
-60% -$33.9M 0.01% 1280
2021
Q3
$57.2M Sell
966,600
-250,800
-21% -$16.5M 0.03% 574
2021
Q2
$81.3M Buy
1,217,400
+79,700
+7% +$5.2M 0.05% 388
2021
Q1
$71.8M Buy
1,137,700
+296,000
+35% +$18.4M 0.05% 347
2020
Q4
$52.2M Sell
841,700
-1,592,800
-65% -$97.9M 0.04% 438
2020
Q3
$139K Buy
2,434,500
+519,700
+27% +$31.3M 0.17% 78
2020
Q2
$105M Buy
1,914,800
+1,305,200
+214% +$78.1M 0.14% 101
2020
Q1
$30.1M Sell
609,600
-235,100
-28% -$14.4M 0.07% 300
2019
Q4
$39.4M Buy
844,700
+900
+0.1% +$51.5K 0.05% 481
2019
Q3
$42.8M Buy
843,800
+43,800
+5% +$2.06M 0.07% 363
2019
Q2
$36.3M Buy
800,000
+581,300
+266% +$27.1M 0.05% 471
2019
Q1
$10.4M Buy
218,700
+68,700
+46% +$3.42M 0.02% 1213
2018
Q4
$7.8M Sell
150,000
-50,000
-25% -$2.69M 0.01% 1281
2018
Q3
$12.4M Buy
200,000
+125,000
+167% +$7.42M 0.02% 1152
2018
Q2
$4.15M Sell
75,000
-325,000
-81% -$17.6M 0.01% 1925
2018
Q1
$25.3M Buy
400,000
+225,000
+129% +$14.5M 0.03% 755
2017
Q4
$10.7M Buy
+175,000
New +$10.9M 0.01% 1288
2017
Q3
Sell
-375,000
Closed -$20.9M 3515
2017
Q2
$20.9M Buy
+375,000
New +$20.4M 0.04% 653
2017
Q1
Sell
-500,000
Closed -$29.2M 3496
2016
Q4
$29.2M Buy
500,000
+420,000
+525% +$23M 0.06% 450
2016
Q3
$4.31M Buy
+80,000
New +$5.14M 0.01% 1426
2015
Q4
Sell
-150,000
Closed -$8.88M 3423
2015
Q3
$8.88M Sell
150,000
-300,000
-67% -$19M 0.02% 1001
2015
Q2
$29.9M Buy
+450,000
New +$29.7M 0.06% 440
2015
Q1
Sell
-105,800
Closed -$6.25M 3585
2014
Q4
$6.25M Sell
105,800
-1,617,900
-94% -$91.2M 0.01% 1239
2014
Q3
$88.2M Buy
1,723,700
+678,300
+65% +$33.9M 0.22% 67
2014
Q2
$50.7M Buy
1,045,400
+389,700
+59% +$19.2M 0.14% 141
2014
Q1
$34.1M Sell
655,700
-397,000
-38% -$21.1M 0.1% 245
2013
Q4
$56M Buy
1,052,700
+810,900
+335% +$41.3M 0.18% 101
2013
Q3
$11.2M Buy
+241,800
New +$10.6M 0.04% 620

Other funds holding BMY

Millennium Management's BMY Position: Q1 2026 in Review

Millennium Management increased its Bristol-Myers Squibb (BMY) stake by 780% in Q1 2026, buying an estimated $338M and bringing the position to 6,545,442 shares worth $397M. The position accounts for 0.17% of the portfolio, ranked #93.

Millennium Management first reported a position in BMY in Q2 2013 and has held it in 51 quarters since. The position peaked at $480M in Q4 2024. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Millennium Management held 6,545,442 shares of Bristol-Myers Squibb worth $397M as of Q1 2026.
  • Millennium Management bought 5,801,783 Bristol-Myers Squibb shares in Q1 2026, an estimated $338M.
  • Bristol-Myers Squibb made up 0.17% of Millennium Management's portfolio in Q1 2026, its #93 holding.
  • Millennium Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 51 quarters since.
  • Millennium Management's Bristol-Myers Squibb position peaked at $480M in Q4 2024.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.